reference/421923

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/421923

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	352
issn	1470-2045
issueIdentifier	4
pageRange	345-352
publicationName	The Lancet. Oncology
startingPage	345
bibliographicCitation	Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012 Apr;13(4):345–52. doi: 10.1016/s1470-2045(11)70373-4. PMID: 22265697.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_52228e100bfae25b8b48174e4dfbd610 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c90e0c75db14dc075136662a8f1b64d http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-5705-1739 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e717c369c2a4ea2b1c7d4aa11c35a4dd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_efbdae5f3a31bd165270df27f43f8bdd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_85bcee6ddb18723415010b000269a4e4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_46b18f6c135db023a3e9461d1ae01f18 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a72d0b90439e1fe1807700c995c82d0f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_82e30cdb0b17d310517d10064383d670 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c1fec7c93cfef2799d09501001da0864 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7b635d10a4ac1274e6eb096bf06df8ee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6a147610dd0fe7856e17a5b8bd32b423
date	201204
identifier	https://doi.org/10.1016/s1470-2045%2811%2970373-4 https://pubmed.ncbi.nlm.nih.gov/22265697
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/27004 https://portal.issn.org/resource/ISSN/1470-2045
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
discusses	http://id.nlm.nih.gov/mesh/M0014878 http://id.nlm.nih.gov/mesh/M0021024 http://id.nlm.nih.gov/mesh/M0026217 http://id.nlm.nih.gov/mesh/M0021911 http://id.nlm.nih.gov/mesh/M0495206 http://id.nlm.nih.gov/mesh/M0238999 http://id.nlm.nih.gov/mesh/M0028048 http://id.nlm.nih.gov/mesh/M0456327
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D009570Q000008 http://id.nlm.nih.gov/mesh/D013629Q000008 http://id.nlm.nih.gov/mesh/D047072Q000008 http://id.nlm.nih.gov/mesh/D020360 http://id.nlm.nih.gov/mesh/D017273Q000008 http://id.nlm.nih.gov/mesh/D014230Q000008 http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D000971Q000008
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D001943Q000473 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D009376Q000601 http://id.nlm.nih.gov/mesh/D009367 http://id.nlm.nih.gov/mesh/D001943Q000601 http://id.nlm.nih.gov/mesh/D009376Q000188 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D017697 http://id.nlm.nih.gov/mesh/D000077384 http://id.nlm.nih.gov/mesh/D014230Q000009 http://id.nlm.nih.gov/mesh/D009570Q000009 http://id.nlm.nih.gov/mesh/D018719Q000378 http://id.nlm.nih.gov/mesh/D000328
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733526 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_e8ad08f759b2798c1b5dca78861cc6ce http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5d445780815638f183c8f68566998507 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_43830973f74de180729ad1e755d592ad http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7428 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9350 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10298 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5311128 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2187 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128713593 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129769972 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136286542

Total number of triples: 73.